

# Non-Insulin Therapies for Diabetes-India Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/N6D6C2E72D2MEN.html>

Date: May 2018

Pages: 142

Price: US\$ 2,980.00 (Single User License)

ID: N6D6C2E72D2MEN

## Abstracts

### Report Summary

Non-Insulin Therapies for Diabetes-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Non-Insulin Therapies for Diabetes industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole India and Regional Market Size of Non-Insulin Therapies for Diabetes 2013-2017, and development forecast 2018-2023

Main market players of Non-Insulin Therapies for Diabetes in India, with company and product introduction, position in the Non-Insulin Therapies for Diabetes market  
Market status and development trend of Non-Insulin Therapies for Diabetes by types and applications

Cost and profit status of Non-Insulin Therapies for Diabetes, and marketing status

Market growth drivers and challenges

The report segments the India Non-Insulin Therapies for Diabetes market as:

India Non-Insulin Therapies for Diabetes Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North India

Northeast India

East India

South India

West India

India Non-Insulin Therapies for Diabetes Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-glucosidase Inhibitors

Amylin Agonists

Biguanides

Dipeptidyl Peptidase-4 (DPP4) Inhibitors

Glinides / Meglitinides

GLP-1 Analogs / GLP-1 Agonists

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

Sulfonylureas

Thiazolidinediones

Others

India Non-Insulin Therapies for Diabetes Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Hospital Pharmacy

Retail Pharmacies

Online Pharmacy

Others

India Non-Insulin Therapies for Diabetes Market: Players Segment Analysis (Company  
and Product introduction, Non-Insulin Therapies for Diabetes Sales Volume, Revenue,  
Price and Gross Margin):

GSK

Eli Lilly

Sumitomo Dainippon Pharma

Intarcia Therapeutics

Servier

Jiangsu Hansoh Pharmaceutical

Novo Nordisk

Emisphere

Uni-Bio Science Group

Takeda  
3SBio  
Merck  
Dong-A Pharmaceutical  
Luye Pharma Group  
Eurofarma  
Geropharm  
Alkem Labs  
SatRx  
Pfizer  
Jiangsu Hengrui Medicine

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF NON-INSULIN THERAPIES FOR DIABETES**

- 1.1 Definition of Non-Insulin Therapies for Diabetes in This Report
- 1.2 Commercial Types of Non-Insulin Therapies for Diabetes
  - 1.2.1 Alpha-glucosidase Inhibitors
  - 1.2.2 Amylin Agonists
  - 1.2.3 Biguanides
  - 1.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  - 1.2.5 Glinides / Meglitinides
  - 1.2.6 GLP-1 Analogs / GLP-1 Agonists
  - 1.2.7 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  - 1.2.8 Sulfonylureas
  - 1.2.9 Thiazolidinediones
  - 1.2.10 Others
- 1.3 Downstream Application of Non-Insulin Therapies for Diabetes
  - 1.3.1 Hospital Pharmacy
  - 1.3.2 Retail Pharmacies
  - 1.3.3 Online Pharmacy
  - 1.3.4 Others
- 1.4 Development History of Non-Insulin Therapies for Diabetes
- 1.5 Market Status and Trend of Non-Insulin Therapies for Diabetes 2013-2023
  - 1.5.1 United States Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023
  - 1.5.2 Regional Non-Insulin Therapies for Diabetes Market Status and Trend 2013-2023

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Non-Insulin Therapies for Diabetes in United States 2013-2017
- 2.2 Consumption Market of Non-Insulin Therapies for Diabetes in United States by Regions
  - 2.2.1 Consumption Volume of Non-Insulin Therapies for Diabetes in United States by Regions
  - 2.2.2 Revenue of Non-Insulin Therapies for Diabetes in United States by Regions
- 2.3 Market Analysis of Non-Insulin Therapies for Diabetes in United States by Regions
  - 2.3.1 Market Analysis of Non-Insulin Therapies for Diabetes in New England 2013-2017

2.3.2 Market Analysis of Non-Insulin Therapies for Diabetes in The Middle Atlantic 2013-2017

2.3.3 Market Analysis of Non-Insulin Therapies for Diabetes in The Midwest 2013-2017

2.3.4 Market Analysis of Non-Insulin Therapies for Diabetes in The West 2013-2017

2.3.5 Market Analysis of Non-Insulin Therapies for Diabetes in The South 2013-2017

2.3.6 Market Analysis of Non-Insulin Therapies for Diabetes in Southwest 2013-2017

2.4 Market Development Forecast of Non-Insulin Therapies for Diabetes in United States 2018-2023

2.4.1 Market Development Forecast of Non-Insulin Therapies for Diabetes in United States 2018-2023

2.4.2 Market Development Forecast of Non-Insulin Therapies for Diabetes by Regions 2018-2023

## **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Non-Insulin Therapies for Diabetes in United States by Types

3.1.2 Revenue of Non-Insulin Therapies for Diabetes in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Non-Insulin Therapies for Diabetes in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Non-Insulin Therapies for Diabetes in United States by Downstream Industry

4.2 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Major Countries

4.2.1 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in New England

4.2.2 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry

in The Middle Atlantic

4.2.3 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in The Midwest

4.2.4 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in The West

4.2.5 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in The South

4.2.6 Demand Volume of Non-Insulin Therapies for Diabetes by Downstream Industry in Southwest

4.3 Market Forecast of Non-Insulin Therapies for Diabetes in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

5.1 United States Economy Situation and Trend Overview

5.2 Non-Insulin Therapies for Diabetes Downstream Industry Situation and Trend Overview

## **CHAPTER 6 NON-INSULIN THERAPIES FOR DIABETES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

6.1 Sales Volume of Non-Insulin Therapies for Diabetes in United States by Major Players

6.2 Revenue of Non-Insulin Therapies for Diabetes in United States by Major Players

6.3 Basic Information of Non-Insulin Therapies for Diabetes by Major Players

6.3.1 Headquarters Location and Established Time of Non-Insulin Therapies for Diabetes Major Players

6.3.2 Employees and Revenue Level of Non-Insulin Therapies for Diabetes Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 NON-INSULIN THERAPIES FOR DIABETES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 GSK

- 7.1.1 Company profile
- 7.1.2 Representative Non-Insulin Therapies for Diabetes Product
- 7.1.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of GSK
- 7.2 Eli Lilly
  - 7.2.1 Company profile
  - 7.2.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.2.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.3 Sumitomo Dainippon Pharma
  - 7.3.1 Company profile
  - 7.3.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.3.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Sumitomo Dainippon Pharma
- 7.4 Intarcia Therapeutics
  - 7.4.1 Company profile
  - 7.4.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.4.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Intarcia Therapeutics
- 7.5 Servier
  - 7.5.1 Company profile
  - 7.5.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.5.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Servier
- 7.6 Jiangsu Hansoh Pharmaceutical
  - 7.6.1 Company profile
  - 7.6.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.6.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Jiangsu Hansoh Pharmaceutical
- 7.7 Novo Nordisk
  - 7.7.1 Company profile
  - 7.7.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.7.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Novo Nordisk
- 7.8 Emisphere
  - 7.8.1 Company profile
  - 7.8.2 Representative Non-Insulin Therapies for Diabetes Product
  - 7.8.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Emisphere

## 7.9 Uni-Bio Science Group

### 7.9.1 Company profile

### 7.9.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.9.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Uni-Bio Science Group

## 7.10 Takeda

### 7.10.1 Company profile

### 7.10.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.10.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Takeda

## 7.11 3SBio

### 7.11.1 Company profile

### 7.11.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.11.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of 3SBio

## 7.12 Merck

### 7.12.1 Company profile

### 7.12.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.12.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Merck

## 7.13 Dong-A Pharmaceutical

### 7.13.1 Company profile

### 7.13.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.13.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Dong-A Pharmaceutical

## 7.14 Luye Pharma Group

### 7.14.1 Company profile

### 7.14.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.14.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Luye Pharma Group

## 7.15 Eurofarma

### 7.15.1 Company profile

### 7.15.2 Representative Non-Insulin Therapies for Diabetes Product

### 7.15.3 Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin of Eurofarma

## 7.16 Geropharm

## 7.17 Alkem Labs

## 7.18 SatRx

## 7.19 Pfizer



7.20 Jiangsu Hengrui Medicine

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

8.1 Industry Chain of Non-Insulin Therapies for Diabetes

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

9.1 Cost Structure Analysis of Non-Insulin Therapies for Diabetes

9.2 Raw Materials Cost Analysis of Non-Insulin Therapies for Diabetes

9.3 Labor Cost Analysis of Non-Insulin Therapies for Diabetes

9.4 Manufacturing Expenses Analysis of Non-Insulin Therapies for Diabetes

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF NON-INSULIN THERAPIES FOR DIABETES**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Non-Insulin Therapies for Diabetes-India Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/N6D6C2E72D2MEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6D6C2E72D2MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970